Pioglitazone increases adiponectin levels in nondiabetic patients with coronary artery disease

Snehal R. Patel, Lynn M. Mailloux, John T. Coppola, Catalin Mindrescu, Cezar S. Staniloae

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

OBJECTIVES: Hypoadiponectinemia is associated with coronary artery disease (CAD). Pioglitazone has been shown to increase levels of adiponectin in diabetic patients. We sought to assess whether administration of pioglitazone to patients with CAD and without diabetes would affect plasma adiponectin levels and endothelial function. METHODS: Seventeen patients with stable CAD and without evidence of diabetes were treated for 12 weeks with pioglitazone hydrochloride 30 mg daily. Adiponectin levels and endothelium-dependent flow-mediated vasodilation (ED-FMD) measurements were obtained pretreatment, posttreatment, and after a 12-week washout period. RESULTS: Treatment with pioglitazone increased adiponectin levels from an average of 10.6 to 21.1 μg/ml (P=0.001) and improved ED-FMD from 4.45 to 8.43% (P=0.001). CONCLUSION: Treatment with pioglitazone increased plasma adiponectin levels and improved ED-FMD in patients with stable CAD and no evidence of diabetes or insulin resistance.

Original languageEnglish (US)
Pages (from-to)349-353
Number of pages5
JournalCoronary Artery Disease
Volume19
Issue number5
DOIs
StatePublished - Aug 2008
Externally publishedYes

Fingerprint

pioglitazone
Adiponectin
Coronary Artery Disease
Vasodilation
Endothelium
Insulin Resistance

Keywords

  • Adiponectin
  • Coronary artery disease
  • Endothelial function
  • Pioglitazone

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Pioglitazone increases adiponectin levels in nondiabetic patients with coronary artery disease. / Patel, Snehal R.; Mailloux, Lynn M.; Coppola, John T.; Mindrescu, Catalin; Staniloae, Cezar S.

In: Coronary Artery Disease, Vol. 19, No. 5, 08.2008, p. 349-353.

Research output: Contribution to journalArticle

Patel, Snehal R. ; Mailloux, Lynn M. ; Coppola, John T. ; Mindrescu, Catalin ; Staniloae, Cezar S. / Pioglitazone increases adiponectin levels in nondiabetic patients with coronary artery disease. In: Coronary Artery Disease. 2008 ; Vol. 19, No. 5. pp. 349-353.
@article{3f0d938c5fe5416badb8cebdf49bd020,
title = "Pioglitazone increases adiponectin levels in nondiabetic patients with coronary artery disease",
abstract = "OBJECTIVES: Hypoadiponectinemia is associated with coronary artery disease (CAD). Pioglitazone has been shown to increase levels of adiponectin in diabetic patients. We sought to assess whether administration of pioglitazone to patients with CAD and without diabetes would affect plasma adiponectin levels and endothelial function. METHODS: Seventeen patients with stable CAD and without evidence of diabetes were treated for 12 weeks with pioglitazone hydrochloride 30 mg daily. Adiponectin levels and endothelium-dependent flow-mediated vasodilation (ED-FMD) measurements were obtained pretreatment, posttreatment, and after a 12-week washout period. RESULTS: Treatment with pioglitazone increased adiponectin levels from an average of 10.6 to 21.1 μg/ml (P=0.001) and improved ED-FMD from 4.45 to 8.43{\%} (P=0.001). CONCLUSION: Treatment with pioglitazone increased plasma adiponectin levels and improved ED-FMD in patients with stable CAD and no evidence of diabetes or insulin resistance.",
keywords = "Adiponectin, Coronary artery disease, Endothelial function, Pioglitazone",
author = "Patel, {Snehal R.} and Mailloux, {Lynn M.} and Coppola, {John T.} and Catalin Mindrescu and Staniloae, {Cezar S.}",
year = "2008",
month = "8",
doi = "10.1097/MCA.0b013e3282fd5c37",
language = "English (US)",
volume = "19",
pages = "349--353",
journal = "Coronary Artery Disease",
issn = "0954-6928",
publisher = "Lippincott Williams and Wilkins",
number = "5",

}

TY - JOUR

T1 - Pioglitazone increases adiponectin levels in nondiabetic patients with coronary artery disease

AU - Patel, Snehal R.

AU - Mailloux, Lynn M.

AU - Coppola, John T.

AU - Mindrescu, Catalin

AU - Staniloae, Cezar S.

PY - 2008/8

Y1 - 2008/8

N2 - OBJECTIVES: Hypoadiponectinemia is associated with coronary artery disease (CAD). Pioglitazone has been shown to increase levels of adiponectin in diabetic patients. We sought to assess whether administration of pioglitazone to patients with CAD and without diabetes would affect plasma adiponectin levels and endothelial function. METHODS: Seventeen patients with stable CAD and without evidence of diabetes were treated for 12 weeks with pioglitazone hydrochloride 30 mg daily. Adiponectin levels and endothelium-dependent flow-mediated vasodilation (ED-FMD) measurements were obtained pretreatment, posttreatment, and after a 12-week washout period. RESULTS: Treatment with pioglitazone increased adiponectin levels from an average of 10.6 to 21.1 μg/ml (P=0.001) and improved ED-FMD from 4.45 to 8.43% (P=0.001). CONCLUSION: Treatment with pioglitazone increased plasma adiponectin levels and improved ED-FMD in patients with stable CAD and no evidence of diabetes or insulin resistance.

AB - OBJECTIVES: Hypoadiponectinemia is associated with coronary artery disease (CAD). Pioglitazone has been shown to increase levels of adiponectin in diabetic patients. We sought to assess whether administration of pioglitazone to patients with CAD and without diabetes would affect plasma adiponectin levels and endothelial function. METHODS: Seventeen patients with stable CAD and without evidence of diabetes were treated for 12 weeks with pioglitazone hydrochloride 30 mg daily. Adiponectin levels and endothelium-dependent flow-mediated vasodilation (ED-FMD) measurements were obtained pretreatment, posttreatment, and after a 12-week washout period. RESULTS: Treatment with pioglitazone increased adiponectin levels from an average of 10.6 to 21.1 μg/ml (P=0.001) and improved ED-FMD from 4.45 to 8.43% (P=0.001). CONCLUSION: Treatment with pioglitazone increased plasma adiponectin levels and improved ED-FMD in patients with stable CAD and no evidence of diabetes or insulin resistance.

KW - Adiponectin

KW - Coronary artery disease

KW - Endothelial function

KW - Pioglitazone

UR - http://www.scopus.com/inward/record.url?scp=58149125347&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=58149125347&partnerID=8YFLogxK

U2 - 10.1097/MCA.0b013e3282fd5c37

DO - 10.1097/MCA.0b013e3282fd5c37

M3 - Article

C2 - 18580598

AN - SCOPUS:58149125347

VL - 19

SP - 349

EP - 353

JO - Coronary Artery Disease

JF - Coronary Artery Disease

SN - 0954-6928

IS - 5

ER -